Skip to content

Optimal patient Selection for CArdiac ResynchronisationTherapy using Molecular Imaging

Optimal patient Selection for CArdiac ResynchronisationTherapy using Molecular Imaging - SCART-MI

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37507
Enrollment
91
Registered
2012-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure Left ventricular dyssynchrony

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Informed consent obtained -Chronic heart failure; -New York Heart Association functional class II, III or IV; -QRS duration >=150 ms for NYHA class II or >=120 ms for NYHA class III/IV; -Optimal pharmacological therapy; -Left ventricular ejection fraction

Exclusion criteria

Exclusion criteria: -Contraindications for implantation of a CRT device; -Age

Design outcomes

Primary

MeasureTime frame
The main study parameters are: -99mTc-Tetrofosmin(MPS)-based dyssynchrony and infarct burden measurements -123I-metaiodobenzylguanidine(MIBG)-based Heart-to-Mediastinum(H/M)-ratio and washout measurements -Mismatch in regional distribution between MPS and MIBG The main study parameters will be compared to response to CRT as defined by: A: Reduction in NYHA class and increase in LVEF >= 5% or B: Reduction in LVESV >= 15%. or C: A composite of A + B.

Secondary

MeasureTime frame
in patients with CRT-D implants, MPS/MIBG mismatch will be correlated to adequate discharge of the defibrillator and/or documented ventricular arrhythmia during the follow-up period.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)